Improvement in Function after Lasmiditan Treatment: Post Hoc Analysis of Data from Phase 3 Studies von Smith, Timothy, Krege, John H., Rathmann, Suchitrita S., Dowsett, Sherie A., Hake, Ann, Nery, Emel S. M., Matthews, Brandy R., Doty, Erin G.

Volltext

Improvement in Function after Lasmiditan Treatment: Post Hoc Analysis of Data from Phase 3 Studies von Smith, Timothy, Krege, John H, Suchitrita S Rathmann, Dowsett, Sherie A, Hake, Ann, Nery, Emel SM, Matthews, Brandy R, Doty, Erin G

Volltext bestellen

Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial von Sims, John R, Zimmer, Jennifer A, Evans, Cynthia D, Lu, Ming, Ardayfio, Paul, Sparks, JonDavid, Wessels, Alette M, Shcherbinin, Sergey, Wang, Hong, Monkul Nery, Emel Serap, Collins, Emily C, Solomon, Paul, Salloway, Stephen, Apostolova, Liana G, Hansson, Oskar, Ritchie, Craig, Brooks, Dawn A, Mintun, Mark, Skovronsky, Daniel M

Volltext

Donanemab in Early Symptomatic Alzheimer’s Disease: Efficacy and Safety in TRAILBLAZER‐ALZ 2, a Phase 3 Randomized Clinical Trial von Mintun, Mark, Ritchie, Craig W, Solomon, Paul, Sims, John R., Salloway, Stephen, Hansson, Oskar, Apostolova, Liana G., Zimmer, Jennifer A., Evans, Cynthia D., Lu, Ming, Ardayfio, Paul A, Sparks, JonDavid, Wessels, Alette M, Shcherbinin, Sergey, Wang, Hong, Nery, Emel Serap Monkul, Collins, Emily C., Dennehy, Ellen B, Brooks, Dawn A., Skovronsky, Daniel M.

Volltext